Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced that it will project the first live transmission case demonstration in the USA of its breakthrough and CE Mark-approved DESolve® 100 Novolimus Eluting Bioresorbable Coronary Scaffold System at the 26th annual Transcatheter Cardiovascular Technologies (TCT) Conference in Washington, DC on Tuesday, Sept. 16. This follows on the heels of a live case transmission on Saturday, Sept. 13th with the DESolve® Novolimus Eluting Bioresorbable Coronary Scaffold System. The Elixir-sponsored symposium is scheduled on Monday, Sept. 15.
Help employers find you! Check out all the jobs and post your resume.
